However, additional combinatory induction with IL-2 and rapamycin was shown to stabilize FoxP3 expression in these cells (113, 124), which enabled the first successful application of iTregs as GVHD-prophylactic therapy to humans (125). Here, FOXP3 is linked to graft versus host disease.